[1] | Stanghellini V, De Ponti F, De Giorgio R, et al. New developments in the treatment of functional dyspepsia. Drugs 2003; 63 (9): 869-92. |
[2] | Farinha P, Gascoyne RD. Helicobacter pylori and MALT Lymphoma. Gastroenterology 2005 May; 128(6): 1579-605. |
[3] | Garcia-Altes A, Jovell AJ, Serra-Part M, et al. Management of Helicobacter pylori in duodenal ulcer: a cost-effectiveness analysis. Aliment Pharmacol Ther 2000 Dec; 14 (12): 1631-8. |
[4] | Nasrat AM. The world misconception and misbehavior towards Helicobacter pylori is leading to major spread of illness. The 7th Anti-Aging Medicine World Congress, Monte-Carlo, Monaco, 2009 Mar. Available from URL, www.euromedicom.com. |
[5] | Nasrat AM, Nasrat SAM, Nasrat RM, et al. Misconception and misbehavior towards Helicobacter pylori is leading to major spread of illness. Gen Med 2015; S1 (002). [Open Access] |
[6] | McColl K, Murray L, el-Omar E, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Eng J Med 1998; 339: 1869-74. |
[7] | Moayyedi P, Soo S, Deeks J, et al. Systemic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Goup. BMJ 2000 Sep 16; 321 (7262): 659-64. |
[8] | Midolo PD, Lambert JR, Hull R, et al. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol. 1995 Oct; 79(4); 475-9. |
[9] | Phull PS, Halliday D, Price AB, et al. Absence of dyspeptic symptoms as a test for Helicobacter pylori eradication. BMJ 1996 Feb 10; 312 (7027): 349-50. |
[10] | Nasrat AM, Nasrat SAM, Nasrat RM, et al. An alternate natural remedy for symptomatic relief of Helicobacter pylori dyspepsia. Gen Med 2015; 3 (4). [Open Access] |
[11] | Matsuo S, Mizuta Y, Hayashi T, et al. Mucosa-associated lymphoid tissue lymphoma of the transverse colon: a case report. World J Gastroenterol 2006 Sep 14; 12 (34): 5573-6. |
[12] | Grünberger B, Wöhrer S, Streubel B, et al. Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma. J Clin Oncol 2006 Mar 20; 24 (9):1370-5. |
[13] | Nasrat RM, Nasrat MM, Nasrat AM, et al. Improvement of idiopathic cardiomyopathy after colon clear. J Cardiol Res 2015. [Open Access] |
[14] | Kubo N, Kochi S, Ariyama I, et al. Pseudomembranous colitis after Helicobacter pylori eradication therapy. Kansenshogaku Zasshi 2006 Jan; 80 (1): 51-5. |
[15] | Schweigart U, Franck H, Schepp W, et al. Toxic megacolon after Helicobacter pylori eradication therapy. Internist (Berl) 1997 Apr; 38 (4): 352-4. |
[16] | Andreoli TE. Cecil Essentials of Medicine. WB Saunders Company. 2001; 5th Ed: 334. |
[17] | Baron S. Baron’s medical microbiology. Churchill Livingstone. 2000; 4th Ed: 346. |
[18] | Zentilin P, Iiritano E, Vingale C, et al. Helicobacter pylori infection is not involved in the Pathogenesis of either erosive or non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003 Apr; 17(8): 1057-64. |
[19] | Volk WA, Gebhardt BM, Hammarskjold M-L, et al. Essential of Medical Microbiology. Lippincott – Raven. 1996; 5th Ed: 377. |
[20] | Cotran RS, Kumar V, Collins T. Robins Pathologic Basis of Disease. WB Saunders Company. 1999; 6th Ed: 790. |
[21] | Sleigh JD, Timbury MC. Notes on Medical Microbiology. Churchill Livingstone. 1998; 5th Ed: 232. |
[22] | Issing WJ. Gastroesophageal reflux – a common illness. Laryngorhinootologie 2003 Feb; 82 (2): 118-22. |
[23] | Labenz J, Blum AL, Bayerdorffer E, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442: 47. |
[24] | Sharma P, Vakil N. Review article: Helicobacter pylori and reflux disease. Aliment Pharmacol Ther 2003 Feb; 17 (3): 297-305. |
[25] | Vakil N. Gastroesophageal reflux disease and Helicobacter pylori infection. Rev Gastroenterol Disord 2003 Winter; 3 (1):1-7. |
[26] | Keskin D, Toroglu S. Studies on antimicrobial activities of solvent extracts of different species. J Environ Biol 2011 Mar; 32 (2): 251-6. |
[27] | Guarizel L, Costa JC, Dutra LB, et al. Anti-inflammatory, laxative and intestinal motility effects of Senna macranthera leaves. Nat Prod Res 2012; 26 (4): 331-43. |
[28] | Ge Z. Potential of fumarate reductase as a novel therapeutic target in Helicobacter pylori infection. Expert Opin Ther Targets 2002Apr; 6(2): 135-46. |
[29] | Mendz GL, Hazell SL, Burns BP. Glucose utilization and lactate production by Helicobacter pylori. J Gen Microbiol 1993 Dec; 139 (Pt 12): 3023-8. |
[30] | Mendz GL, Hazell SL. Fumarate catabolism in Helicobacter pylori. Biochem Mol Biol Int. 1993 Oct; 31(2): 325-32. |
[31] | Mendz GL, Hazell SL, van Gorkom L. Pyruvate metabolism in Helicobacter pylori. Arch Microbiol. 1994; 162(3):187-92. |
[32] | Hughes NJ, Clayton CL, Chalk PA, et al. Helicobacter pylori porCDAB oorDABC genes encode distinct pyruvate: flavodoxin and 2-oxoglutarate: acceptor oxidoreductases which mediate electron transport to NADP. J Bacteriol 1998 Mar; 180(5): 1119-28. |
[33] | Berg JM, Tymoczko JL, Stryer L. Biochemistry. WH Freeman and Company. 2002; 5th Ed: 480. |
[34] | Mendz GL, Ball GE, Meek DJ, Pyruvate metabolism in Campylobacter spp. Biochim Biophys Acta 1997 Mar 15; 1334 (2-3): 291-302. |
[35] | Sears CL. A dynamic partnership: Celebrating our gut flora. Anaerobe 2005 Oct; 11 (5): 247-51. |
[36] | O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006 Jul; 7 (7): 688-93. |
[37] | Flint HJ, O’Toole PW, Walker AW. The human intestinal microbiota. Microbilogy 2010 Nov; 156 (11): 3203-4. |
[38] | Asaka M. Epidemiology of Helicobacter pylori infection in Japan. Nippon Rinsho 2003 Jan; 61(1): 19-24. |
[39] | Cirak MY, Ozdek A, Yilmaz D, et al. Detection of Helicobacter pylori and its CagA gene in tonsil and adenoid tissues by PCR. Arch Otolaryngol Head Neck Surg. 2003 Nov; 129 (11): 1225-9. |